Filtered By:
Drug: Estradiol
Therapy: Endocrine Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 41 results found since Jan 2013.
The Application of 18F-FES PET in Clinical Cancer Care: A Systematic Review
CONCLUSIONS: [18F]fluoroestradiol PET is not only a convenient and accurate diagnostic imaging tool for detecting ER-expressing lesions in patients with breast and ovarian cancer but also among patients with uterine cancer. [18F]fluoroestradiol PET is a noninvasive predictive and monitoring tool for treatment response and prognosis.PMID:37482660 | DOI:10.1097/RLU.0000000000004760
Source: Clinical Genitourinary Cancer - July 24, 2023 Category: Cancer & Oncology Authors: Ya-Ting Huang Tom Wei-Wu Chen Li-Yu Chen Ya-Yao Huang Yen-Shen Lu Source Type: research
Chinese medicinal herbs for reducing endocrine therapy-induced side effects in patients with hormone receptor-positive breast cancer: a systematic review and meta-analysis
CONCLUSIONS: CMH combined with complementary therapy can moderately reduce endocrine therapy-induced side effects, including bone loss and dyslipidemia in patients with HR + breast cancer, revealing the potential role of CMH in treating (HR+) breast cancer. More high-quality RCTs are warranted to further validate the effectiveness and safety of CMH.PMID:37096936 | DOI:10.1080/13880209.2023.2203193
Source: Pharmaceutical Biology - April 25, 2023 Category: Drugs & Pharmacology Authors: Shaoqing Chen Yifang Gao Haichao Liu Jin Jing Zhengyu Yang Haoming Zhu Bairui Chen Yu Wang Ting Zhang Shizhong Wang Jianping Lin Source Type: research
Novel 11 β-substituted Estradiol Conjugates: Transition from ERα Agonists to Effective PROTAC Degraders
J Steroid Biochem Mol Biol. 2022 Jul 20:106154. doi: 10.1016/j.jsbmb.2022.106154. Online ahead of print.ABSTRACTEndocrine therapy is widely used in clinic for breast cancer treatment, but long-term treatment inevitably causes drug resistance. Most of endocrine therapy-resistant breast cancers continue to depend on ERα signaling for growth and survival. In this regard, small molecule-induced ERα degradation, i.e. proteolysis targeting chimeras (PROTACs), represents an effective strategy to overcome endocrine resistance. Herein, we describe the design, synthesis, and biological evaluation of novel ERα-targeting PROTACs, w...
Source: Mol Biol Cell - July 23, 2022 Category: Molecular Biology Authors: Guoshun Luo Xinyu Li Xin Lin Xiang Lu Zhenbang Li Hua Xiang Source Type: research
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor
Nat Commun. 2022 Jun 6;13(1):3127. doi: 10.1038/s41467-022-30898-0.ABSTRACTEstrogen and progesterone receptor (ER, PR) signaling control breast development and impinge on breast carcinogenesis. ER is an established driver of ER + disease but the role of the PR, itself an ER target gene, is debated. We assess the issue in clinically relevant settings by a genetic approach and inject ER + breast cancer cell lines and patient-derived tumor cells to the milk ducts of immunocompromised mice. Such ER + xenografts were exposed to physiologically relevant levels of 17-β-estradiol (E2) and progesterone (P4). We find that independe...
Source: Cancer Control - June 6, 2022 Category: Cancer & Oncology Authors: Valentina Scabia Ayyakkannu Ayyanan Fabio De Martino Andrea Agnoletto Laura Battista Csaba Laszlo Assia Treboux Khalil Zaman Athina Stravodimou Didier Jallut Maryse Fiche Philip Bucher Giovanna Ambrosini George Sflomos Cathrin Brisken Source Type: research
Global transcriptome analysis reveals partial estrogen-like effects of karanjin in MCF-7 breast cancer cells
Gene. 2022 Apr 18:146507. doi: 10.1016/j.gene.2022.146507. Online ahead of print.ABSTRACTKaranjin, an abundantly occurring furanoflavonoid in edible and non-edible legumes, exerts diverse biological effects in vivo, and in vitro. Its potential as an anticancer agent is gaining traction following recent demonstrations of its anti-proliferative, cell cycle inhibitory, and pro-apoptotic effects. However, the genomic correlates of these activities are not known. In the present study we delineated the transcriptomic footprint of 10 μM karanjin in MCF-7 breast cancer cells, using next generation sequencing technology (RNA-seq)....
Source: Gene - April 21, 2022 Category: Genetics & Stem Cells Authors: Gaurav Bhatt Akshita Gupta Latha Rangan Anil Mukund Limaye Source Type: research
Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ER α expression and proliferation in luminal primary and metastatic breast cancer cells
CONCLUSIONS: CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs.PMID:35418303 | DOI:10.1186/s13046-022-02360-y
Source: Cancer Control - April 14, 2022 Category: Cancer & Oncology Authors: Sara Pescatori Stefano Leone Manuela Cipolletti Stefania Bartoloni Alessandra di Masi Filippo Acconcia Source Type: research
